Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Jeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, Steven R Steinhubl, Gilles Montalescot, Mingyuan Shao, Werner Hacke, Keith A Fox, Peter B Berger, Eric J Topol, A Michael Lincoff

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The association between bleeding severity and cause of mortality in the non-acute setting is unclear. We sought to investigate the association between bleeding and mortality subtype, and assess whether this association differs in patients on dual antiplatelet therapy (DAPT) versus aspirin alone.
Original languageEnglish
Pages (from-to)98-105.e1
JournalAmerican Heart Journal
Volume162
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial'. Together they form a unique fingerprint.

Cite this